Natalizumab antibody | AbD21375_hIgG1

100% Secure


Human anti Natalizumab:HRP

Anti-natalizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format, suitable for bioanalytical assays for natalizumab and biosimilars. It is recommended as detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.

Human anti Natalizumab

Anti-natalizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format, suitable for bioanalytical assays for natalizumab and biosimilars. It is recommended as detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.

Product Type
Monoclonal Antibody
Clone
AbD21375_hIgG1
Isotype
IgG1
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
HCA249P E 0.1 mg
HCA249 E 0.1 mg
Human anti natalizumab, clone AbD21375_hIgG1 is a Type 1 anti-idiotypic antibody that specifically recognizes free natalizumab but not free human alpha4-beta1 integrin or the drug/ alpha4-beta1 integrin complex. Clone AbD21375_hIgG1 inhibits the binding of natalizumab to alpha4-beta1 integrin and can be used to measure free natalizumab levels in serum from patients.This clone can also be used for pharmacokinetic (PK) assay development or in the development and calibration of anti-drug antibody (ADA) assays.

Natalizumab, marketed under the brand name Tysabri®, is a humanized IgG4/kappa monoclonal antibody approved as a monotherapy for the treatment of relapsing forms of multiple sclerosis and for the treatment of Crohn’s disease. Natalizumab is also being evaluated for potential clinical use in the treatment of B-cell malignancies. This therapeutic antibody, directed against alpha-4 integrin (CD49d), binds to alpha-4/beta-1 integrin on the surface of circulating leucocytes. It is believed to act by blocking the interaction of alpha-4/beta-1 integrin with vascular cell adhesion molecule-1 (VCAM-1), preventing the adherence and transport of inflammatory immune cells across the intestinal lining and blood-brain barrier.

Clone AbD21375_hIgG1 is one of a range of Type 1 (HCA248, HCA250), anti-idiotypic antibodies to natalizumab available from Bio-Rad and forms part of a wider and expanding portfolio of anti-idiotypic antibodies that have been developed for the detection of biotherapeutics.

Product Details

Product Form
Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
Product Form
Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.01% Thiomersal
Preservative Stabilisers
0.01% Thiomersal
Immunogen
Natalizumab
Affinity
The monovalent intrinsic affinity of this antibody was measured as KD = 2.1 nM by real time, label free molecular interaction analysis on immobilized natalizumab.
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
IgG concentration 0.5 mg/ml

Storage Information

Storage
Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use
Shelf Life
12 months from date of despatch
Shelf Life
12 months from date of despatch

More Information

Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Tysabri® is a registered trademark Biogen Idec and Elan.
Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Tysabri® is a registered trademark Biogen Idec and Elan.
Licensed Use
For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory
For research purposes only

Applications of Natalizumab antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA
ELISA
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
ELISA
This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA248 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
ELISA
This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA248 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
This antibody is fully human and can be used as a reference standard in an ADA assay.
Protocol: ADA bridging ELISA

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
Hispec Assay Diluent BUF049A 50 ml E IY
Human anti Natalizumab HCA248 0.1 mg E
Human anti Natalizumab HCA250 0.1 mg E
Hispec Assay Diluent BUF049A 50 ml E IY
Human anti Natalizumab HCA248 0.1 mg E
Human anti Natalizumab HCA250 0.1 mg E
LYNX Rapid HRP Antibody Conjugation Kit LNK001P 1 Conjugation For 400µg Antibody CJ
LYNX Rapid HRP Antibody Conjugation Kit LNK002P 3 Conjugations For 400µg Antibody CJ
LYNX Rapid HRP Antibody Conjugation Kit LNK003P 1 Conjugation For 4mg Antibody CJ
LYNX Rapid HRP Antibody Conjugation Kit LNK004P 5 Conjugations For 4mg Antibody CJ
LYNX Rapid HRP Antibody Conjugation Kit LNK005P 1 Conjugation For 20mg Antibody CJ
LYNX Rapid HRP Antibody Conjugation Kit LNK006P 3 Conjugations For 40µg Antibody CJ
Mouse anti Human IgG (Fc) CH2 Domain:HRP MCA647P 0.2 mg C* E

Product Specific References

References for Natalizumab antibody

  1. Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
    US Patent US20170315118A1